KahnS.E., HaffnerS.M., HeiseM.A., HermanW.H., HolmanR.R., JonesN.P.Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.N Engl J Med2006; 355: 2427–43.
2.
VasudevanA., BalasubramanyamA.Thiazolidinediones: a review of their mechanisms of insulin sensitisation, therapeutic potential, clinical efficacy, and tolerability.Diabetes Technol Ther2004; 6: 850–63.
3.
NissenS.E., WolskiK.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.N Engl J Med2007; 356: 2457–71.
4.
LagoR.M., SinghP.P., NestoR.W.Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.Lancet2007; 370(9593): 1129–36.
5.
LinS.H., KinY.F., KuoS.W., HsuY.J., HungY.J.Rosiglitazone improves glucose metabolism in non diabetic uremic patients on CAPD.Am J Kidney Dis2003; 42: 774–80.
6.
WongT.Y., SzetoC.C., ChowK.M., LeungC.B., LamC.W., LiP.K.Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis.Am J Kidney Dis2005; 46: 713–18.
7.
HaraldssonB.Assessing the individual peritoneal dialysis capacities of individual patients. A clinical tool based on the three pore model.Kidney Int1995; 47: 1187–98.
8.
La MiliaV., PozzoniP., VirgaG., CrepaldiM., Del VecchioL., AndrulliS.Peritoneal transport assessment by PET with 3.86% glucose: a long-term prospective evaluation.Kidney Int2006; 69: 927–33.
9.
KarallieddeJ., BuckinghamR., StarkieM., LorandD., StewartM., VibertiG.Effect of various diuretic treatments on rosiglitazone-induced fluid retention.J Am Soc Nephrol2006; 17: 3482–90.
10.
QayyumR., AdomaityteJ.A meta-analysis of the effect of thiazolidinediones on blood pressure.J Clin Hypertens (Greenwich)2006; 8: 19–28.
11.
BuchananT.A., MeehanW.P., JengY.Y., YangD., ChanT.M., NadlerJ.L.Blood pressure lowering by pioglitazone, evidence for a direct vascular effect.J Clin Invest1995, 96: 354–60.
12.
CalnekD.S., MazzellaL., RoserS., RomanJ., HartC.M.Peroxisome proliferator-activated receptor gamma ligands increase the release of nitric oxide from endothelial cells.Arterioscler Thromb Vasc Biol2003; 23: 52–7.
13.
MazièreC., MeignotteA., DantinF., ConteM.A., MazièreJ.C.Oxidized LDL induces an oxidative stress and activates the tumor suppressor P53 in MRC5 human fibroblasts.Biochem Biophys Res Commun2000; 276: 718–23.
